Q-omics provides the consensus-scored CDKN1C profile across patient tissues and cancer cell-line models. CDKN1C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CDKN1C is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CDKN1C RNA expression shows 14,537 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where CDKN1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDKN1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDKN1C survival associations across molecular data types. CDKN1C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDKN1C RNA expression–survival associations across cancer types. High CDKN1C expression shows unfavorable associations in LUAD, UCEC, KICH and SKCM, but favorable associations in KIRP and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for CDKN1C RNA expression.
This table summarizes CDKN1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDKN1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDKN1C shows lower tumor expression in KIRC, KICH, KIRP, LUAD, BLCA and THCA. The KIRC box plot shows higher CDKN1C RNA expression in normal versus tumor tissue (log2 FC = −1.717, t-test p < 0.001).
This table shows molecular features associated with CDKN1C in patient tissues and cancer cell lines. In patient samples, CDKN1C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDKN1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and OVARY.
